China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will ...

, opens new tab said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up ...

Eli Lilly And Co (NYSE:LLY) has reportedly reached a settlement agreement with a medi spa that sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, which ...

(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its ...

Eli Lilly and Company announced on Tuesday that the National Medical Products Administration (NMPA) in China has approved the ...

, opens new tab weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 5%. Lilly said it expects significant production ...

Eli Lilly’s (NYSE:LLY) weight-loss drug Zepbound (tirzepatide) will remain in short supply through April-end amid increased ...

Eli Lilly & Co. said Wednesday that two late-stage trials evaluating a 10 mg or 15 mg injection of tirzepatide — the weight-loss drug marketed in the U.S. as Zepbound — reduced the severity of ...

We raise our Eli Lilly fair value estimate to $540 from $500 following stronger-than-expected first-quarter results. In particular, pricing drove 10 percentage points of the 26% top-line growth ...

Tuesday, Eli Lilly And Co (NYSE:LLY) reported first-quarter revenue of $8.77 billion, up 26% year over year, marginally missing the consensus of $8.92 billion, driven by increases of 16% in volume and ...

Eli Lily’s weight-loss drug tirzepatide has been shown to “significantly” reduce sleep apnoea severity, the US drugs giant said on Wednesday. The firm said phase 3 clinical trials had showed ...